Background
Acute pulmonary exacerbation (APE) in cystic fibrosis patients is
frequent and associated with a decline in pulmonary function, quality of
life and survival. Tobramycin is often used in regimens requiring
activity against Pseudomonas aeruginosa , however, an important
number of centers do not use official dosing recommendation. The current
dosing strategy may be suboptimal.